Contribute Try STAT+ Today

Good morning, everyone, and nice to see you again. We have finally returned from an extended break and, not surprisingly, are playing a bit of catch-up thanks to mounds of emails and other curious missives that arrived in our absence. To cope, yes, we are firing up the coffee kettle and brewing cups of needed stimulation. Our choice today is Jack Daniels (once again, folks, this is a real thing) and we invite you to join us. Remember, no prescription nor vaccine card is needed. Meanwhile, here are some tidbits to start you on your journey today. We hope all goes well and, as always, request that you keep us in mind when secret dossiers emerge and saucy tips can be passed on. …

A Biden administration plan to lower prescription-drug prices backs legislation from congressional Democrats, including a push to empower the federal government to negotiate for drug prices in Medicare and pass those lower costs to the private sector, The Wall Street Journal reports. The road map goes further, however, by outlining administrative actions by agencies and departments that could come in concert with possible legislative changes. Administrative measures include testing reimbursement for drugs in Medicare based on the clinical value they provide to patients and offering federal funding for research into new treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment